

## Komplementární a alternativní medicína v urologii

**KURT DREIKORN**

*Department of Urology, Klinikum Bremen-Mitte, Bremen, Germany*

### LITERATURA

- 1 Fair WR. Back to the future – the role of complementary medicine in urology. *J Urol* 1999; **162**: 411–20
- 2 Moyad MA. Complementary medicine in urology. *Urol Clin N Am* 2002; **29**: xv–xvi
- 3 Zimmerman RA, Thompson IM. Prevalence of complementary medicine in urologic practice. A review of recent studies with emphasis and use among prostate cancer patients. *Urol Clin N Am* 2002; **29**: 1–9
- 4 Doggweiler-Wiygul R. Complementary medicine in urology – a different approach. *World J Urol* 2002; **20**: 271–318
- 5 McClure MW. An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. *World J Urol* 2002; **20**: 273–84
- 6 The United Kingdom Parliament. House of Lords. Science and Technology-Sixth Report 21 November 2000 <http://www.parliament.the-stationeryoffice.co.uk/pa/ld199900/ldselect/ldsctech/123/12301.htm>
- 7 Department of Health. *Government Response to the House of Lords Select Committee on Science and Technology's Report on complementary and alternative medicine*, March 2001 <http://www.archive.official-documents.co.uk/document/cm51/5124/5124.pdf>
- 8 Dacgnelie PD, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. *BJU Int* 2004; **93**: 1139–50
- 9 Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. *Curr Opin Urol* 2004; **14**: 143–9
- 10 Kirby RS, Fitzpatrick JM. How should we advise patients about the chemoprevention of prostate cancer? *BJU Int* 2005; **96**: 231–2
- 11 Ernst E. Harmless herbs? A review of the recent literature. *Am J Med* 1998; **104**: 170–8
- 12 NIH. <http://hccam.nih.gov/health/alerts/spes/>
- 13 Oh WK, Small EJ. PC-SPES and prostate cancer. *Urol Clin N Am* 2002; **29**: 59–66
- 14 Mydlo JH. The impact of obesity in urology. *Urol Clin N Am* 2004; **31**: 275–87
- 15 Moyad MA. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. *Urology* 2002; **59**: 41–50
- 16 Moyad MA. Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer? *Urol Clin N Am* 2002; **29**: 115–24
- 17 Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer. Part I. Time to redirect our attention? *Urol Clin N Am* 2004; **31**: 289–300
- 18 Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer. Part II. Time to redirect our attention? *Urol Clin N Am* 2004; **31**: 301–11
- 19 Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless. Part I. *Urol Clin N Am* 2004; **31**: 249–57
- 20 Moyad MA, Barada JH, Lue TF, Mulhall JP, Goldstein I, Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless. Part II. *Urol Clin N Am* 2004; **31**: 259–73
- 21 Gupta S, Mukhtar H. Green tea and prostate cancer. *Urol Clin N Am* 2002; **29**: 49–57
- 22 Wilt TJ, Ishani A, Stark G *et al*. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. *JAMA* 1998; **280**: 1604–9
- 23 Wilt TJ. Phytotherapy. In Chapple CR, McConnell JD, Tubaro A eds. *Benign Prostatic Hyperplasia*. London: Martin Dunitz, 2000: 39–63
- 24 Dreikorn K, Lowe FC, Borkowski A *et al*. Other medical therapies. In Chatelain C, Denis L, Foo KT, Khoury S, McConnel JD eds. *Benign Prostatic Hyperplasia*. Plymouth: Plymbridge Distributors Ltd, 2001: 479–511

- 25 **Dreikorn K, Berges R, Pientka L, Jonas M.** Phytotherapie bei BPH. Aktuelle evidenzbasierte Bewertung. *Urologe [a]* 2002; **41**: 447–51
- 26 **Madersbacher S, Schatzl G, Brössner C, Dreikorn K.** Phytotherapie bei BPS. *Urologe [a]* 2005; **44**: 513–20
- 27 **Dreikorn K, Fitzpatrick JM.** Phytotherapeutic agents in the treatment of LUTS and BPH. In Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P eds, *Textbook of Benign Prostatic Hyperplasia*. London and New York: Taylor & Francis, 2005: 415–27
- 28 **Fagelman EF, Lowe FC.** Herbal medications in the treatment of benign prostatic hyperplasia (BPH). *Urol Clin N Am* 2002; **29**: 23–9
- 29 **Nelson MA, Reid M, Duffield-Lillico AJ, Marshall JR.** Prostate cancer and selenium. *Urol Clin N Am* 2002; **29**: 67–70
- 30 **Clark LC, Combs GF Jr, Turnbull BW et al.** For the Nutritional Prevention of Cancer Study Group: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomised clinical trial. *JAMA* 1996; **76**: 1957–66
- 31 **Clark LC, Dodkin B, Krongrad A et al.** Decreased incidence of prostate cancer with selenium supplementation, results of a double-blind cancer prevention trial. *Br J Urol* 1998; **81**: 730–4
- 32 **Duffield-Lillico AJ, Dalkin BL, Reid ME et al.** Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. *BJU Int* 2003; **91**: 608–12
- 33 **Fleshner NE.** Vitamin E and prostate cancer. *Urol Clin N Am* 2002; **29**: 107–13
- 34 **Moyad MA.** Selenium and vitamin E supplements for prostate cancer: Evidence or embellishment? *Urology* 2002; **59** (Suppl. 4A): 9–19
- 35 **Hyman M, Pizzorno J, Weil A.** A rational approach to antioxidant therapy and vitamin E. *Alternative Therapies* 2005; **11**: 14–7
- 36 **The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group.** The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994; **330**: 1029–35
- 37 **Heinonen OP, Albanes D, Virtomo J et al.** Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. *J Natl Cancer Inst* 1998; **90**: 440–6
- 38 **The HOPE and HOPE-TOO Trial Investigators.** Effects of long term vitamin E supplementation on cardiovascular events and cancer. A randomised controlled trial. *JAMA* 2005; **293**: 1138–347
- 39 **Miller ER, Pastor-Barriuso R, Dalod D, Riemersma RA, Appel LJ, Guallar E.** Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med* 2005; **142**: 37–46
- 40 **Guallar E, Hanley DF, Miller ER III.** An editorial update: Annus horribilis for vitamin E. *Ann Int Med* 2005; **143**: 143–5
- 41 **Greenberg ER.** Editorial: Vitamin E supplements: Good in theory, but is the theory good? *Ann Intern Med* 2005; **142**: 75–6
- 42 **Anonymous.** Letter to the editor. *Ann Intern Med* 2005; **143**: 150–8
- 43 **Pitkin RM, Branagan MA, Burmeister LF.** Accuracy of data in abstracts of published research articles. *JAMA* 1999; **281**: 1110–1
- 44 **Lee I-Min, Cook NR, Gaziano JM et al.** Vitamin E in the primary prevention of cardiovascular disease and cancer. *JAMA* 2005; **294**: 56–65
- 45 **Cook NR, Stampfer MJ, Ma J et al.** Beta-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. *Cancer* 1999; **86**: 1783–92
- 46 **Malila N, Taylor PR, Virtonen MJ et al.** Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland) *Cancer Causes Control* 2002; **13**: 617–23
- 47 **Miller EC, Giovannucci E, Erdmann JW, Bahnson R, Schwartz SJ, Clinton SK.** Tomato products, lycopene, and prostate cancer risk. *Urol Clin N Am* 2002; **20**: 83–93
- 48 **Castle EP, Thrasher B.** The role of soy phytoestrogens in prostate cancer. *Urol Clin N Am* 2002; **29**: 71–81
- 49 **Leitzmann MF, Stampfer MJ, Wu K, Colditz Ga Willet WC, Giovannucci EL.** Zinc supplement use and risk of prostate cancer. *J Natl Cancer Inst* 2003; **95**: 1004–7
- 50 **Yarnell E.** Botanical medicines for the urinary tract. *World J Urol* 2002; **20**: 285–93
- 51 **Schoonen WM, Salinas CA, Kiemene ALM, Stomford JL.** Alcohol consumption and risk of prostate cancer in middleaged men. *Int J Cancer* 2005; **113**: 133–40
- 52 **Webb PM, Pundie DM, Bain CJ.** Alcohol, wine and risk of epithelial ovarian cancer. *Cancer Epidem Biom Prevent* 2004; **13**: 592–9
- 53 **Briggs NC, Levine RS, Bobo LD.** Wine drinking and risk of non-Hodgkin's lymphoma among men in the United States: a population-based

study. *Am J Epidemiol* 2002;  
156: 454–62

**Korespondence:**

Prof Dr med. Kurt Dreikorn,  
Department of Urology,  
Klinikum Bremen-Mitte,  
St.-Juergenstrasse 1,

28177 Bremen, Germany.  
e-mail: [dreikorn@uni-bremen.de](mailto:dreikorn@uni-bremen.de)

**Zkratky:**

**CAM**, complementary and  
alternative medicine; **NCCAM**,  
National Center for Complementary  
and Alternative Medicine; **NIH**,

(USA) National Institute of Health;  
**ED**, erectile dysfunction; **ATBC**,  
Alpha-Tocopherol-Beta Carotene  
Cancer Prevention (study); **HOPE**,  
Heart Outcomes Prevention  
Evaluation Study.